Q2 FY2026 · ended Jun 30, 2026 · Revenue $26,955, -97.8% YoY · Filed Aug 12, 2026
Vyome Holdings, Inc. (HIND) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $26,955 and a net loss of $685,556. As of Jun 30, 2026 it held $7.9 million in cash and investments and $17,310 in total debt.
Revenue
$26,955
-97.8% vs year-ago quarter
Net income
$-685,556
-122.0% vs year-ago quarter
Operating cash flow
$-903,712
-195.1% vs year-ago quarter
Free cash flow
—
EPS
$-0.10
+100.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
7.02M
+160.6% vs year-ago quarter
Net cash
$7.87M
Q2 FY2026
Operating margin
-9190.1%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HIND (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Clemente, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1427570
- Former names
- ReShape Lifesciences Inc. (until Aug 14, 2025); OBALON THERAPEUTICS INC (until Jun 21, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $26,955 | $31,591 | $36,551 | $34,627 | $1.2M |
| Operating income | -$862,566 | -$1.1M | -$1.4M | -$8.6M | -$324,189 |
| Net income | -$685,556 | -$962,910 | -$1.2M | -$8.4M | -$308,760 |
| Diluted EPS | -$0.10 | -$0.15 | -$0.21 | -$3.12 | -$799.90 |
| Operating cash flow | -$903,712 | -$1.4M | -$1.5M | -$1.8M | -$306,251 |
| Total assets | $9.2M | $10.2M | $6.5M | $7.0M | $9.0M |
| Total liabilities | $1.9M | $2.1M | $2.7M | $3.1M | $3.2M |
| Stockholders' equity | $7.3M | $8.0M | $3.8M | $3.9M | — |
| Cash and investments | $7.9M | $8.8M | $5.0M | $5.7M | $4.1M |
| Total debt | $17,310 | $22,548 | — | $38,609 | $104,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Aug 28, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 25, 2026 | Aug 25, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
May 29, 2026 | May 28, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Apr 29, 2026 | Apr 24, 2026 |
All 693 Vyome Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.